News Archiv


‍US FDA Medical Device Registration of Aladuck405/II
‍
‍NutraIngredients-Awardsgranted for clinical study project with the food supplement 5-ALA + SFC as animmune system enhancer for COVID-19 vaccines
‍
‍Photonamic and PhotonicsHealthcare strengthen collaboration after successful clinical pilot study ofoxygen measurement technology
‍
‍Photonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy (“PDT”) in the Field of Non-Small Cell Lung Cancer (NSCLC)
‍
‍FerroSens’ FIDscreen prototype devices successfully applied in clinicalstudy during blood donation
‍
‍First-in-Human Study for New Application of Photodynamic Therapy with 5-Aminolevulinic Acid for Extracorporeal Photopheresis
‍
First Patient Enrolled in Phase 2 Trial with Interstitial Photodynamic Therapy
‍
Brustkrebsoperionen mit 5-ALA, Artikel aus Pinneberger Tageblatt
‍
‍Results of Phase II Trial for Breast Cancer Surgery Published in Breast Cancer Research
‍
‍Pinneberger Pharmafirma arbeitet an Urintest zur Krebsfrüherkennung
‍
‍First Patient Enrolled in Pivotal Phase 3 Trial for Breast Conserving Surgery
‍
Artikel aus Pinneberger Tageblatt, April 2021:
Pinneberger Pharma-Unternehmen: Medikament gegen Covid verträglich / Wirksamkeit deutet sich an.
‍
photonamic Acquires Majority Stake in FerroSens
‍
‍Research with 5-ALA phosphate and  Sodium Ferrous Citrate in COVID-19 patients
‍
Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals
‍
Medexus Announces Expanded Availability of Gleolan® in Canada
‍
Case Reports on Treatment with 5-ALA Phosphate for Patients with New Coronavirus Infection (COVID-19)
‍
NX DEVELOPMENT CORP. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan®
‍
NX DEVELOPMENT CORP IN THE USA LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL